Newsroom
Articles > Legal Troubles Plague Erasca, Inc. as Stock Tumbles and Class Action Lawsuits Pile Up
- Erasca, Inc. (ERAS) faces a securities class action lawsuit after its stock plummeted following accusations of patent infringement and a patient death.
- Multiple law firms, including Faruqi & Faruqi, LLP and Pomerantz Law Firm, are accepting claims from investors who suffered losses due to ERAS stock.
- The lawsuits cover the period between January 14, 2025 and April 26, 2026, seeking to hold Erasca accountable for alleged securities law violations.
- Investors who purchased ERAS securities during the Class Period have until August 10, 2026, to seek lead plaintiff status in the ongoing legal battle.
- The Schall Law Firm and Berger Montague PC are among the various firms offering legal representation for investors affected by the ERAS stock decline.
Erasca, Inc. (NASDAQ: ERAS) finds itself embroiled in a legal battle as a securities class action unfolds against the company. The trouble began when Revolution Medicines (RevMed) accused Erasca of patent infringement related to ERAS-0015, a pan-RAS molecular glue aimed at treating solid tumors. The news of this accusation, along with the unfortunate death of a patient who received ERAS-0015, led ERAS stock to tumble by $9.25 (-48%).
Seeking to represent investors who bought or otherwise acquired Erasca common stock between January 14, 2025, and April 26, 2026, the securities class action lawsuit highlights the serious allegations leveled against the company. As the legal battle intensifies, multiple law firms, including Faruqi & Faruqi, LLP and Pomerantz Law Firm, are stepping forward to assist investors in seeking compensation for their losses.
Faruqi & Faruqi, LLP, a prominent national securities law firm, encourages investors who suffered losses due to Erasca's alleged securities law violations to contact their Securities Litigation Partner, James (Josh) Wilson, directly. Wilson is available to discuss legal options with investors who purchased Erasca securities during the specified Class Period.
Pomerantz Law Firm, in a similar vein, has filed a class action lawsuit against Erasca, Inc., advising investors who incurred losses on their Erasca investments to reach out. Investors are urged to contact Danielle Peyton at newaction@pomlaw.com or call 646-581-9980 for further guidance on participating in the legal proceedings.
Kahn Swick & Foti, LLC and Bronstein, Gewirtz & Grossman LLC are also actively involved in representing investors affected by the ERAS stock decline. These firms are diligently working to ensure that investors who purchased Erasca securities during the Class Period between January 14, 2025, and April 26, 2026, are fairly compensated for any losses incurred.
As the legal landscape surrounding Erasca, Inc. grows more complex, investors who wish to take action against the company have until August 10, 2026, to seek lead plaintiff status in the ongoing securities fraud class action lawsuit. With multiple law firms, including Glancy Prongay Wolke & Rotter LLP and Berger Montague PC, offering their services, affected investors have the opportunity to hold Erasca accountable for the alleged violations that led to significant stock losses.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Legal Troubles Plague Erasca, Inc. as Stock Tumbles and Class Action Lawsuits Pile Up
By KlickAnalytics Data Insights | June 30, 2026 08:02PM ET
Key Points
- Erasca, Inc. (ERAS) faces a securities class action lawsuit after its stock plummeted following accusations of patent infringement and a patient death.
- Multiple law firms, including Faruqi & Faruqi, LLP and Pomerantz Law Firm, are accepting claims from investors who suffered losses due to ERAS stock.
- The lawsuits cover the period between January 14, 2025 and April 26, 2026, seeking to hold Erasca accountable for alleged securities law violations.
- Investors who purchased ERAS securities during the Class Period have until August 10, 2026, to seek lead plaintiff status in the ongoing legal battle.
- The Schall Law Firm and Berger Montague PC are among the various firms offering legal representation for investors affected by the ERAS stock decline.
Erasca, Inc. (NASDAQ: ERAS) finds itself embroiled in a legal battle as a securities class action unfolds against the company. The trouble began when Revolution Medicines (RevMed) accused Erasca of patent infringement related to ERAS-0015, a pan-RAS molecular glue aimed at treating solid tumors. The news of this accusation, along with the unfortunate death of a patient who received ERAS-0015, led ERAS stock to tumble by $9.25 (-48%).
Seeking to represent investors who bought or otherwise acquired Erasca common stock between January 14, 2025, and April 26, 2026, the securities class action lawsuit highlights the serious allegations leveled against the company. As the legal battle intensifies, multiple law firms, including Faruqi & Faruqi, LLP and Pomerantz Law Firm, are stepping forward to assist investors in seeking compensation for their losses.
Faruqi & Faruqi, LLP, a prominent national securities law firm, encourages investors who suffered losses due to Erasca's alleged securities law violations to contact their Securities Litigation Partner, James (Josh) Wilson, directly. Wilson is available to discuss legal options with investors who purchased Erasca securities during the specified Class Period.
Pomerantz Law Firm, in a similar vein, has filed a class action lawsuit against Erasca, Inc., advising investors who incurred losses on their Erasca investments to reach out. Investors are urged to contact Danielle Peyton at newaction@pomlaw.com or call 646-581-9980 for further guidance on participating in the legal proceedings.
Kahn Swick & Foti, LLC and Bronstein, Gewirtz & Grossman LLC are also actively involved in representing investors affected by the ERAS stock decline. These firms are diligently working to ensure that investors who purchased Erasca securities during the Class Period between January 14, 2025, and April 26, 2026, are fairly compensated for any losses incurred.
As the legal landscape surrounding Erasca, Inc. grows more complex, investors who wish to take action against the company have until August 10, 2026, to seek lead plaintiff status in the ongoing securities fraud class action lawsuit. With multiple law firms, including Glancy Prongay Wolke & Rotter LLP and Berger Montague PC, offering their services, affected investors have the opportunity to hold Erasca accountable for the alleged violations that led to significant stock losses.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.